Gimv has accomplished its funding into the Apraxon Group, a number one homecare supplier specializing in wound care companies in Germany. This transaction is a part of a joint progress plan with the corporate’s founder and CEO Oliver Pokrzewinski, who will proceed to be an necessary shareholder within the firm.
Apraxon, (Hofbieber (DE) – apraxon.com), gives top quality wound look after (largely aged) individuals affected by persistent wounds in a homecare setting. Typical wound indications embrace decubitus, diabetic foot or ulcus cruris. In offering this service, the corporate acts as an middleman between sufferers, medical doctors, nursing companies or properties and insurance coverage corporations.
Because of its excessive diploma of specialization, Apraxon constantly offers top quality medical care and is ready to tailor the remedy course of in response to every affected person’s particular person wants. In a market with steadily growing affected person numbers, primarily pushed by demographic change, specialised medical care is gaining in significance. Companies offered are reimbursed by medical health insurance corporations, for whom Apraxon has been a dependable associate for a few years.
‘I’m satisfied that Gimv is the suitable associate to appreciate the corporate’s progress ambitions and increase Apraxon’s footprint in Germany,’ explains Oliver Pokrzewinski, Managing Director and CEO of Apraxon.
‘Because of Apraxon’s clear dedication to high quality, extremely certified nursing workers and strongly digitised and scalable processes, we consider that Apraxon is the suitable platform to construct a real chief within the German wound care market. We’re very a lot trying ahead to supporting Mr. Pokrzewinski and your entire Apraxon crew in realising their bold progress plans,’ says Philipp v. Hammerstein, Associate at Gimv within the Well being & Care crew in Munich.
The brand new funding marks Gimv’s fifth acquisition within the German-speaking healthcare market over the past 4 years. Gimv at the moment has 23 participations in corporations within the healthcare and life sciences sector. This acquisition additional underpins Gimv’s place as probably the most energetic European buyers within the healthcare business and its ambition to positively contribute to the United Nations Sustainable Growth Targets of fine well being and well-being. The Gimv portfolio additionally contains a number of clinic and apply teams, in addition to medical expertise and biotech corporations
GIMV Investeringsmaatschappij Voor Vlanderen NV printed this content material on 14 April 2021 and is solely accountable for the knowledge contained therein. Distributed by Public, unedited and unaltered, on 14 April 2021 05:32:03 UTC.